| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV-1 | 264 | 2024 | 6938 | 13.190 |
Why?
|
| Drug Resistance, Viral | 110 | 2023 | 820 | 10.430 |
Why?
|
| Anti-HIV Agents | 185 | 2023 | 4256 | 8.870 |
Why?
|
| HIV Infections | 300 | 2024 | 16718 | 8.470 |
Why?
|
| Reverse Transcriptase Inhibitors | 64 | 2023 | 615 | 5.570 |
Why?
|
| HIV Reverse Transcriptase | 33 | 2020 | 213 | 4.650 |
Why?
|
| HIV Fusion Inhibitors | 24 | 2013 | 81 | 4.090 |
Why?
|
| Viral Load | 103 | 2023 | 3300 | 3.830 |
Why?
|
| Lamivudine | 39 | 2021 | 342 | 3.690 |
Why?
|
| Zidovudine | 47 | 2021 | 620 | 3.040 |
Why?
|
| RNA, Viral | 105 | 2023 | 2902 | 2.750 |
Why?
|
| HIV Integrase Inhibitors | 10 | 2023 | 142 | 2.700 |
Why?
|
| Anti-Retroviral Agents | 34 | 2023 | 1715 | 2.630 |
Why?
|
| Antiretroviral Therapy, Highly Active | 45 | 2018 | 1873 | 2.630 |
Why?
|
| Acquired Immunodeficiency Syndrome | 43 | 2023 | 2234 | 2.490 |
Why?
|
| Receptors, CCR5 | 15 | 2016 | 497 | 2.070 |
Why?
|
| Viremia | 20 | 2023 | 736 | 2.030 |
Why?
|
| HIV Envelope Protein gp41 | 17 | 2012 | 314 | 1.900 |
Why?
|
| CD4 Lymphocyte Count | 82 | 2023 | 2559 | 1.740 |
Why?
|
| HIV Integrase | 4 | 2023 | 120 | 1.740 |
Why?
|
| Benzoxazines | 22 | 2020 | 301 | 1.670 |
Why?
|
| Virus Replication | 26 | 2023 | 2534 | 1.580 |
Why?
|
| Piperazines | 22 | 2020 | 2491 | 1.450 |
Why?
|
| HIV | 24 | 2021 | 1604 | 1.420 |
Why?
|
| Drug Resistance, Multiple, Viral | 11 | 2008 | 52 | 1.420 |
Why?
|
| HIV Seropositivity | 9 | 2023 | 971 | 1.360 |
Why?
|
| Pyrrolidinones | 8 | 2014 | 117 | 1.320 |
Why?
|
| Receptors, HIV | 6 | 2016 | 162 | 1.300 |
Why?
|
| Mutation | 76 | 2023 | 29784 | 1.260 |
Why?
|
| HIV Protease Inhibitors | 25 | 2020 | 430 | 1.230 |
Why?
|
| Ritonavir | 24 | 2022 | 322 | 1.200 |
Why?
|
| Virology | 4 | 2010 | 77 | 1.140 |
Why?
|
| Pyrimidines | 15 | 2012 | 2940 | 1.090 |
Why?
|
| Virus Internalization | 6 | 2013 | 501 | 1.040 |
Why?
|
| DNA, Viral | 23 | 2021 | 2226 | 1.000 |
Why?
|
| Peptide Fragments | 21 | 2016 | 5096 | 1.000 |
Why?
|
| Adenine | 10 | 2021 | 936 | 0.930 |
Why?
|
| Treatment Failure | 27 | 2021 | 2619 | 0.890 |
Why?
|
| CD4-Positive T-Lymphocytes | 32 | 2023 | 4385 | 0.890 |
Why?
|
| AIDS Vaccines | 10 | 2016 | 938 | 0.860 |
Why?
|
| Alkynes | 22 | 2020 | 306 | 0.840 |
Why?
|
| Cyclopropanes | 22 | 2020 | 416 | 0.800 |
Why?
|
| Humans | 381 | 2024 | 744220 | 0.790 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 6 | 2020 | 215 | 0.770 |
Why?
|
| Drug Resistance, Microbial | 24 | 2004 | 862 | 0.770 |
Why?
|
| Cyclohexanes | 8 | 2013 | 152 | 0.760 |
Why?
|
| env Gene Products, Human Immunodeficiency Virus | 6 | 2016 | 370 | 0.750 |
Why?
|
| Viral Tropism | 8 | 2016 | 101 | 0.740 |
Why?
|
| Receptors, CXCR4 | 8 | 2016 | 726 | 0.740 |
Why?
|
| Oxazines | 11 | 2023 | 298 | 0.710 |
Why?
|
| Drug Therapy, Combination | 56 | 2018 | 6485 | 0.670 |
Why?
|
| Salvage Therapy | 5 | 2006 | 1275 | 0.650 |
Why?
|
| Pyridones | 10 | 2023 | 712 | 0.650 |
Why?
|
| Microbial Sensitivity Tests | 19 | 2016 | 1877 | 0.650 |
Why?
|
| Polymerase Chain Reaction | 17 | 2020 | 6172 | 0.640 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 5 | 2004 | 648 | 0.640 |
Why?
|
| Lymphocyte Activation | 17 | 2020 | 5523 | 0.640 |
Why?
|
| Proviruses | 9 | 2024 | 318 | 0.630 |
Why?
|
| Didanosine | 11 | 2010 | 153 | 0.600 |
Why?
|
| Stavudine | 7 | 2012 | 85 | 0.580 |
Why?
|
| Clinical Trials as Topic | 19 | 2016 | 7908 | 0.580 |
Why?
|
| HIV Protease | 11 | 2009 | 96 | 0.580 |
Why?
|
| DNA, Circular | 2 | 2015 | 97 | 0.560 |
Why?
|
| Inhibitory Concentration 50 | 3 | 2014 | 459 | 0.550 |
Why?
|
| Dideoxynucleosides | 10 | 2017 | 122 | 0.550 |
Why?
|
| Triazoles | 8 | 2013 | 911 | 0.520 |
Why?
|
| Genotype | 39 | 2021 | 12956 | 0.510 |
Why?
|
| Medication Adherence | 6 | 2014 | 2062 | 0.510 |
Why?
|
| South Africa | 17 | 2023 | 1731 | 0.490 |
Why?
|
| Genes, env | 4 | 2012 | 95 | 0.490 |
Why?
|
| HIV Envelope Protein gp120 | 10 | 2016 | 952 | 0.470 |
Why?
|
| Ethics, Research | 2 | 2006 | 191 | 0.460 |
Why?
|
| Rectum | 2 | 2018 | 904 | 0.460 |
Why?
|
| Virus Latency | 5 | 2024 | 358 | 0.440 |
Why?
|
| Leukocytes, Mononuclear | 14 | 2023 | 1836 | 0.440 |
Why?
|
| Antiviral Agents | 14 | 2022 | 2987 | 0.440 |
Why?
|
| HIV Long Terminal Repeat | 1 | 2012 | 88 | 0.430 |
Why?
|
| Sequence Analysis, DNA | 13 | 2017 | 4803 | 0.430 |
Why?
|
| Drugs, Investigational | 3 | 2012 | 214 | 0.430 |
Why?
|
| Herpesvirus 4, Human | 3 | 2017 | 1043 | 0.420 |
Why?
|
| HIV Antibodies | 8 | 2024 | 1322 | 0.420 |
Why?
|
| Pyridazines | 2 | 2011 | 202 | 0.420 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 6 | 2018 | 5442 | 0.420 |
Why?
|
| Botswana | 10 | 2024 | 1040 | 0.410 |
Why?
|
| Genes, pol | 4 | 2007 | 51 | 0.410 |
Why?
|
| Lab-On-A-Chip Devices | 6 | 2018 | 428 | 0.410 |
Why?
|
| Adult | 129 | 2023 | 214035 | 0.400 |
Why?
|
| Molecular Sequence Data | 26 | 2014 | 18116 | 0.390 |
Why?
|
| Microfluidic Analytical Techniques | 7 | 2017 | 828 | 0.390 |
Why?
|
| Biosensing Techniques | 5 | 2015 | 668 | 0.380 |
Why?
|
| Infectious Disease Transmission, Vertical | 9 | 2021 | 1320 | 0.380 |
Why?
|
| Nevirapine | 10 | 2023 | 267 | 0.380 |
Why?
|
| Amino Acid Substitution | 6 | 2023 | 1792 | 0.380 |
Why?
|
| Mutation, Missense | 7 | 2011 | 2563 | 0.370 |
Why?
|
| Withholding Treatment | 7 | 2019 | 599 | 0.370 |
Why?
|
| RNA-Directed DNA Polymerase | 6 | 2009 | 248 | 0.350 |
Why?
|
| Neutropenia | 3 | 2000 | 895 | 0.340 |
Why?
|
| Stem Cell Transplantation | 3 | 2018 | 1620 | 0.340 |
Why?
|
| AIDS-Related Opportunistic Infections | 5 | 2010 | 657 | 0.330 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 7 | 2012 | 4752 | 0.320 |
Why?
|
| Indinavir | 5 | 2006 | 74 | 0.320 |
Why?
|
| Gene Products, gag | 4 | 2010 | 337 | 0.320 |
Why?
|
| Patient Selection | 7 | 2023 | 4216 | 0.310 |
Why?
|
| Plasma | 6 | 2016 | 575 | 0.310 |
Why?
|
| Male | 125 | 2023 | 350027 | 0.300 |
Why?
|
| Point-of-Care Systems | 8 | 2018 | 1176 | 0.290 |
Why?
|
| Phylogeny | 10 | 2023 | 2803 | 0.290 |
Why?
|
| Cytidine Triphosphate | 2 | 2007 | 17 | 0.280 |
Why?
|
| Female | 125 | 2024 | 380197 | 0.280 |
Why?
|
| Receptors, Virus | 2 | 2009 | 648 | 0.270 |
Why?
|
| Metal Nanoparticles | 3 | 2020 | 405 | 0.270 |
Why?
|
| Virus Integration | 2 | 2018 | 299 | 0.270 |
Why?
|
| T-Lymphocytes, Cytotoxic | 4 | 2001 | 1821 | 0.270 |
Why?
|
| Transplantation, Homologous | 2 | 2018 | 4776 | 0.270 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 2 | 2004 | 227 | 0.260 |
Why?
|
| Nucleic Acid Amplification Techniques | 2 | 2018 | 323 | 0.260 |
Why?
|
| Thymidine | 1 | 2005 | 310 | 0.260 |
Why?
|
| Reagent Kits, Diagnostic | 2 | 2003 | 224 | 0.260 |
Why?
|
| Receptors, Chemokine | 2 | 2015 | 669 | 0.260 |
Why?
|
| Interleukin-12 | 2 | 1998 | 579 | 0.250 |
Why?
|
| Herpesvirus 8, Human | 2 | 2018 | 258 | 0.250 |
Why?
|
| Antibodies, Monoclonal | 6 | 2022 | 9275 | 0.250 |
Why?
|
| Point Mutation | 3 | 2007 | 1624 | 0.250 |
Why?
|
| Amino Acid Sequence | 12 | 2016 | 13817 | 0.250 |
Why?
|
| Sulfonamides | 7 | 2014 | 1940 | 0.240 |
Why?
|
| Epstein-Barr Virus Infections | 2 | 2015 | 572 | 0.240 |
Why?
|
| Interleukin-2 | 2 | 2009 | 1904 | 0.230 |
Why?
|
| Recombination, Genetic | 3 | 2008 | 1586 | 0.230 |
Why?
|
| Codon | 9 | 2007 | 611 | 0.230 |
Why?
|
| Immunocompromised Host | 3 | 2021 | 847 | 0.230 |
Why?
|
| RNA Stability | 3 | 2017 | 322 | 0.230 |
Why?
|
| Electricity | 2 | 2015 | 182 | 0.230 |
Why?
|
| Lymphoma | 2 | 2009 | 1873 | 0.220 |
Why?
|
| Platinum | 3 | 2020 | 233 | 0.220 |
Why?
|
| Sensitivity and Specificity | 15 | 2020 | 14726 | 0.220 |
Why?
|
| United Nations | 1 | 2003 | 165 | 0.220 |
Why?
|
| Severe Acute Respiratory Syndrome | 1 | 2004 | 137 | 0.220 |
Why?
|
| Nelfinavir | 5 | 2017 | 68 | 0.220 |
Why?
|
| Patient Compliance | 9 | 2012 | 2684 | 0.220 |
Why?
|
| Disease Reservoirs | 2 | 2019 | 131 | 0.210 |
Why?
|
| Cell Line | 12 | 2016 | 15999 | 0.210 |
Why?
|
| Treatment Outcome | 34 | 2021 | 63119 | 0.210 |
Why?
|
| Middle Aged | 69 | 2021 | 213367 | 0.210 |
Why?
|
| Phenotype | 17 | 2019 | 16365 | 0.210 |
Why?
|
| Internationality | 2 | 2021 | 1003 | 0.210 |
Why?
|
| DNA Primers | 7 | 2017 | 2892 | 0.210 |
Why?
|
| T-Lymphocytes | 11 | 2020 | 10182 | 0.210 |
Why?
|
| Nanotechnology | 3 | 2013 | 710 | 0.210 |
Why?
|
| pol Gene Products, Human Immunodeficiency Virus | 4 | 2014 | 39 | 0.200 |
Why?
|
| Histone Deacetylase Inhibitors | 2 | 2024 | 789 | 0.200 |
Why?
|
| Filgrastim | 5 | 2004 | 133 | 0.200 |
Why?
|
| Chemoprevention | 2 | 2014 | 319 | 0.190 |
Why?
|
| Antibodies, Immobilized | 2 | 2012 | 26 | 0.190 |
Why?
|
| Delavirdine | 1 | 2000 | 7 | 0.190 |
Why?
|
| Biomedical Research | 1 | 2016 | 3311 | 0.190 |
Why?
|
| CD8-Positive T-Lymphocytes | 12 | 2023 | 4477 | 0.190 |
Why?
|
| Gene Products, env | 4 | 1996 | 263 | 0.180 |
Why?
|
| Lymphocytes | 7 | 2009 | 2617 | 0.180 |
Why?
|
| Drug Therapy | 3 | 2020 | 497 | 0.180 |
Why?
|
| HIV Long-Term Survivors | 2 | 2018 | 126 | 0.180 |
Why?
|
| Drug Administration Schedule | 10 | 2018 | 4929 | 0.180 |
Why?
|
| Integrase Inhibitors | 2 | 2017 | 12 | 0.180 |
Why?
|
| Interferon-alpha | 1 | 2024 | 895 | 0.170 |
Why?
|
| United States Food and Drug Administration | 2 | 2021 | 1583 | 0.170 |
Why?
|
| Personnel, Hospital | 1 | 2021 | 283 | 0.170 |
Why?
|
| Nanostructures | 2 | 2015 | 551 | 0.170 |
Why?
|
| gag Gene Products, Human Immunodeficiency Virus | 4 | 2014 | 222 | 0.170 |
Why?
|
| Pharmacogenetics | 4 | 2011 | 676 | 0.170 |
Why?
|
| Antibodies, Neutralizing | 3 | 2024 | 1978 | 0.170 |
Why?
|
| Randomized Controlled Trials as Topic | 9 | 2020 | 9960 | 0.170 |
Why?
|
| Evolution, Molecular | 7 | 2016 | 1939 | 0.170 |
Why?
|
| Photometry | 2 | 2009 | 58 | 0.170 |
Why?
|
| RNA Splice Sites | 1 | 2020 | 209 | 0.170 |
Why?
|
| Rural Health | 1 | 2020 | 305 | 0.170 |
Why?
|
| Lymphopenia | 1 | 2021 | 285 | 0.170 |
Why?
|
| Models, Biological | 4 | 2010 | 9582 | 0.160 |
Why?
|
| Research Design | 5 | 2013 | 5987 | 0.160 |
Why?
|
| Flow Cytometry | 12 | 2017 | 5974 | 0.160 |
Why?
|
| Vaccines, DNA | 2 | 2010 | 305 | 0.160 |
Why?
|
| Endpoint Determination | 2 | 2005 | 601 | 0.160 |
Why?
|
| Bacterial Infections | 4 | 2015 | 1401 | 0.160 |
Why?
|
| Signal Processing, Computer-Assisted | 2 | 2020 | 1537 | 0.160 |
Why?
|
| Double-Blind Method | 20 | 2021 | 12035 | 0.160 |
Why?
|
| DNA-Directed RNA Polymerases | 1 | 2020 | 371 | 0.160 |
Why?
|
| Developing Countries | 4 | 2007 | 2814 | 0.160 |
Why?
|
| Statistics, Nonparametric | 4 | 2012 | 2886 | 0.160 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2020 | 442 | 0.160 |
Why?
|
| Disease Transmission, Infectious | 2 | 2014 | 547 | 0.150 |
Why?
|
| Streptococcal Infections | 2 | 1992 | 638 | 0.150 |
Why?
|
| Cell Line, Transformed | 3 | 2009 | 898 | 0.150 |
Why?
|
| Pilot Projects | 8 | 2023 | 8321 | 0.150 |
Why?
|
| Reproducibility of Results | 15 | 2020 | 19907 | 0.150 |
Why?
|
| Data Interpretation, Statistical | 2 | 2005 | 2715 | 0.150 |
Why?
|
| Spermatozoa | 1 | 2021 | 625 | 0.150 |
Why?
|
| Recombinant Proteins | 8 | 2004 | 6612 | 0.150 |
Why?
|
| Cohort Studies | 17 | 2020 | 40559 | 0.150 |
Why?
|
| Pregnancy Complications, Infectious | 6 | 2020 | 2026 | 0.140 |
Why?
|
| Nanocomposites | 1 | 2017 | 52 | 0.140 |
Why?
|
| Time Factors | 20 | 2016 | 40063 | 0.140 |
Why?
|
| Lymphoid Tissue | 1 | 2018 | 455 | 0.140 |
Why?
|
| Placebos | 7 | 2021 | 1677 | 0.140 |
Why?
|
| Drug Discovery | 2 | 2016 | 1058 | 0.140 |
Why?
|
| Lymphocyte Count | 5 | 2018 | 793 | 0.140 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 1999 | 252 | 0.140 |
Why?
|
| Killer Cells, Natural | 3 | 2022 | 2133 | 0.140 |
Why?
|
| Infant, Newborn | 11 | 2023 | 25618 | 0.130 |
Why?
|
| Cerebrovascular Disorders | 1 | 2003 | 1504 | 0.130 |
Why?
|
| Base Sequence | 9 | 2020 | 12801 | 0.130 |
Why?
|
| Bacterial Translocation | 1 | 2015 | 73 | 0.130 |
Why?
|
| Research Personnel | 1 | 2020 | 573 | 0.130 |
Why?
|
| Mutagenesis, Site-Directed | 2 | 2010 | 1724 | 0.130 |
Why?
|
| Sarcoma, Kaposi | 1 | 2018 | 370 | 0.130 |
Why?
|
| Unsafe Sex | 1 | 2016 | 220 | 0.130 |
Why?
|
| Dideoxynucleotides | 2 | 2007 | 13 | 0.130 |
Why?
|
| Thymine Nucleotides | 2 | 2007 | 63 | 0.130 |
Why?
|
| Drug Approval | 1 | 2021 | 741 | 0.120 |
Why?
|
| Alternative Splicing | 1 | 2020 | 1118 | 0.120 |
Why?
|
| Pharmaceutical Preparations | 1 | 2023 | 1071 | 0.120 |
Why?
|
| Immunity, Innate | 4 | 2022 | 2958 | 0.120 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 5 | 2015 | 3871 | 0.120 |
Why?
|
| Electrodes | 1 | 2017 | 619 | 0.120 |
Why?
|
| Nitriles | 2 | 2011 | 952 | 0.120 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2016 | 3598 | 0.120 |
Why?
|
| Infection Control | 1 | 2021 | 964 | 0.120 |
Why?
|
| Drug Interactions | 5 | 2022 | 1458 | 0.120 |
Why?
|
| Case-Control Studies | 6 | 2021 | 21752 | 0.120 |
Why?
|
| Viral Envelope Proteins | 3 | 2011 | 635 | 0.120 |
Why?
|
| HIV-Associated Lipodystrophy Syndrome | 3 | 2003 | 138 | 0.120 |
Why?
|
| Tuberculosis | 3 | 2012 | 1912 | 0.110 |
Why?
|
| Patients | 1 | 2020 | 900 | 0.110 |
Why?
|
| Quaternary Ammonium Compounds | 2 | 2011 | 205 | 0.110 |
Why?
|
| Post-Exposure Prophylaxis | 1 | 2014 | 102 | 0.110 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2015 | 214 | 0.110 |
Why?
|
| Lipoproteins, LDL | 1 | 2016 | 639 | 0.110 |
Why?
|
| Mycobacterium chelonae | 1 | 1993 | 11 | 0.110 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2021 | 3328 | 0.110 |
Why?
|
| Chemokine CCL2 | 1 | 2015 | 617 | 0.110 |
Why?
|
| Sequence Homology, Amino Acid | 3 | 2012 | 2839 | 0.110 |
Why?
|
| Cytomegalovirus | 1 | 2017 | 732 | 0.110 |
Why?
|
| Ultrafiltration | 1 | 2012 | 57 | 0.110 |
Why?
|
| Malaria, Falciparum | 1 | 2021 | 1077 | 0.110 |
Why?
|
| Research | 3 | 2017 | 1999 | 0.110 |
Why?
|
| Entropy | 2 | 2011 | 209 | 0.110 |
Why?
|
| Monocytes | 3 | 2019 | 2594 | 0.100 |
Why?
|
| Protease Inhibitors | 3 | 2012 | 791 | 0.100 |
Why?
|
| Virion | 1 | 2014 | 433 | 0.100 |
Why?
|
| Cost-Benefit Analysis | 3 | 2023 | 5396 | 0.100 |
Why?
|
| Genetic Variation | 6 | 2019 | 6546 | 0.100 |
Why?
|
| Immunophenotyping | 6 | 2015 | 1880 | 0.100 |
Why?
|
| Central Nervous System | 1 | 2019 | 1357 | 0.100 |
Why?
|
| Microfluidics | 2 | 2015 | 662 | 0.100 |
Why?
|
| Africa South of the Sahara | 3 | 2020 | 724 | 0.100 |
Why?
|
| Nucleic Acid Conformation | 2 | 2020 | 914 | 0.100 |
Why?
|
| Genome, Viral | 4 | 2018 | 667 | 0.100 |
Why?
|
| Deoxycytidine | 3 | 2014 | 825 | 0.100 |
Why?
|
| Immunity, Humoral | 1 | 2016 | 598 | 0.100 |
Why?
|
| Host-Pathogen Interactions | 3 | 2016 | 1477 | 0.100 |
Why?
|
| Blood Component Removal | 1 | 2012 | 125 | 0.100 |
Why?
|
| Neoplasms | 2 | 2018 | 21672 | 0.100 |
Why?
|
| Transcriptional Activation | 1 | 2018 | 1782 | 0.100 |
Why?
|
| Microchip Analytical Procedures | 1 | 2011 | 29 | 0.100 |
Why?
|
| Radioactive Waste | 2 | 1990 | 8 | 0.100 |
Why?
|
| Antibodies, Blocking | 1 | 2012 | 254 | 0.100 |
Why?
|
| Streptococcus | 1 | 1991 | 197 | 0.100 |
Why?
|
| Amides | 2 | 2011 | 459 | 0.100 |
Why?
|
| Prospective Studies | 13 | 2023 | 53280 | 0.100 |
Why?
|
| High-Throughput Screening Assays | 1 | 2017 | 945 | 0.100 |
Why?
|
| Disease Progression | 7 | 2014 | 13280 | 0.100 |
Why?
|
| Virus Attachment | 1 | 2010 | 55 | 0.100 |
Why?
|
| Goals | 1 | 2016 | 706 | 0.100 |
Why?
|
| United States | 15 | 2021 | 69867 | 0.090 |
Why?
|
| Cytomegalovirus Infections | 1 | 2017 | 821 | 0.090 |
Why?
|
| Rifampin | 1 | 2012 | 315 | 0.090 |
Why?
|
| Blood | 1 | 2013 | 598 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2010 | 10949 | 0.090 |
Why?
|
| Patient Participation | 1 | 2020 | 1457 | 0.090 |
Why?
|
| Leukemia Virus, Murine | 1 | 2010 | 117 | 0.090 |
Why?
|
| Retroviridae Infections | 1 | 2010 | 151 | 0.090 |
Why?
|
| Medical Waste | 1 | 1990 | 14 | 0.090 |
Why?
|
| Waste Products | 1 | 1990 | 12 | 0.090 |
Why?
|
| Gene Deletion | 2 | 2013 | 2751 | 0.090 |
Why?
|
| World Health Organization | 3 | 2013 | 1318 | 0.090 |
Why?
|
| Refuse Disposal | 1 | 1990 | 31 | 0.090 |
Why?
|
| Genes, MHC Class I | 1 | 2010 | 258 | 0.090 |
Why?
|
| Cholesterol, HDL | 1 | 2016 | 1814 | 0.090 |
Why?
|
| Cytokines | 3 | 2021 | 7326 | 0.090 |
Why?
|
| DNA, Complementary | 2 | 2011 | 2050 | 0.090 |
Why?
|
| Adenoviridae | 2 | 2011 | 1099 | 0.090 |
Why?
|
| HIV Antigens | 6 | 2014 | 347 | 0.090 |
Why?
|
| HEK293 Cells | 2 | 2020 | 4201 | 0.090 |
Why?
|
| Microarray Analysis | 1 | 2012 | 766 | 0.090 |
Why?
|
| HLA-B Antigens | 1 | 2010 | 353 | 0.080 |
Why?
|
| Vaccination | 3 | 2011 | 3278 | 0.080 |
Why?
|
| Sterilization | 1 | 1990 | 133 | 0.080 |
Why?
|
| Fatigue Syndrome, Chronic | 1 | 2010 | 214 | 0.080 |
Why?
|
| Optical Devices | 1 | 2009 | 37 | 0.080 |
Why?
|
| Protozoan Infections | 1 | 1988 | 39 | 0.080 |
Why?
|
| Remission Induction | 1 | 2014 | 2389 | 0.080 |
Why?
|
| Myositis | 1 | 1991 | 251 | 0.080 |
Why?
|
| Viruses | 1 | 2012 | 374 | 0.080 |
Why?
|
| Staining and Labeling | 1 | 2013 | 1100 | 0.080 |
Why?
|
| Luciferases | 1 | 2010 | 733 | 0.080 |
Why?
|
| Gene Dosage | 1 | 2012 | 1251 | 0.080 |
Why?
|
| Child | 16 | 2024 | 77679 | 0.080 |
Why?
|
| Reassortant Viruses | 1 | 2007 | 37 | 0.080 |
Why?
|
| Tetanus Toxoid | 2 | 2000 | 193 | 0.080 |
Why?
|
| Antigens, Viral | 4 | 2020 | 1035 | 0.080 |
Why?
|
| Glycerolphosphate Dehydrogenase | 2 | 1985 | 39 | 0.080 |
Why?
|
| Disinfection | 1 | 1990 | 191 | 0.080 |
Why?
|
| Quantum Dots | 1 | 2009 | 172 | 0.080 |
Why?
|
| Government Programs | 1 | 2010 | 275 | 0.080 |
Why?
|
| Tumor Virus Infections | 1 | 2010 | 452 | 0.080 |
Why?
|
| Genitalia, Female | 1 | 1988 | 146 | 0.080 |
Why?
|
| Drug Combinations | 3 | 2020 | 1962 | 0.080 |
Why?
|
| Area Under Curve | 3 | 2010 | 1655 | 0.080 |
Why?
|
| Drug Monitoring | 2 | 2004 | 956 | 0.080 |
Why?
|
| Young Adult | 15 | 2020 | 56436 | 0.080 |
Why?
|
| Cardiovascular Diseases | 2 | 2023 | 15161 | 0.070 |
Why?
|
| Neutrophils | 1 | 2000 | 3717 | 0.070 |
Why?
|
| Case Management | 1 | 2009 | 286 | 0.070 |
Why?
|
| HIV Core Protein p24 | 3 | 2014 | 256 | 0.070 |
Why?
|
| Genital Diseases, Female | 1 | 1988 | 197 | 0.070 |
Why?
|
| AIDS Dementia Complex | 1 | 2008 | 153 | 0.070 |
Why?
|
| Adolescent | 19 | 2020 | 85759 | 0.070 |
Why?
|
| Tamoxifen | 2 | 2022 | 981 | 0.070 |
Why?
|
| Single-Cell Analysis | 1 | 2017 | 2183 | 0.070 |
Why?
|
| Hodgkin Disease | 1 | 2014 | 1415 | 0.070 |
Why?
|
| Pregnancy | 11 | 2020 | 29142 | 0.070 |
Why?
|
| Sequence Alignment | 2 | 2009 | 2256 | 0.070 |
Why?
|
| Purine Nucleosides | 1 | 2006 | 30 | 0.070 |
Why?
|
| Half-Life | 3 | 2017 | 659 | 0.070 |
Why?
|
| Decision Making | 1 | 2020 | 3888 | 0.070 |
Why?
|
| Simian immunodeficiency virus | 1 | 2011 | 846 | 0.070 |
Why?
|
| Acidosis, Lactic | 1 | 2007 | 142 | 0.070 |
Why?
|
| Heterozygote | 1 | 2013 | 2805 | 0.070 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2011 | 840 | 0.070 |
Why?
|
| Dioxolanes | 1 | 2006 | 25 | 0.070 |
Why?
|
| Genes, Reporter | 1 | 2010 | 1547 | 0.070 |
Why?
|
| Virus Activation | 2 | 2018 | 319 | 0.070 |
Why?
|
| Alleles | 4 | 2016 | 6938 | 0.070 |
Why?
|
| Risk | 4 | 2018 | 9685 | 0.070 |
Why?
|
| Likelihood Functions | 1 | 2009 | 1005 | 0.070 |
Why?
|
| Cells, Cultured | 8 | 2018 | 19227 | 0.070 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2013 | 3385 | 0.070 |
Why?
|
| Laboratories | 4 | 2003 | 463 | 0.070 |
Why?
|
| Escherichia coli | 5 | 2001 | 4220 | 0.070 |
Why?
|
| Oxidoreductases, N-Demethylating | 1 | 2005 | 115 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2013 | 6535 | 0.060 |
Why?
|
| National Institute of Allergy and Infectious Diseases (U.S.) | 2 | 2017 | 62 | 0.060 |
Why?
|
| Proportional Hazards Models | 3 | 2012 | 12355 | 0.060 |
Why?
|
| Pyrimidinones | 1 | 2007 | 371 | 0.060 |
Why?
|
| Infant | 9 | 2023 | 35129 | 0.060 |
Why?
|
| Candida | 3 | 2009 | 172 | 0.060 |
Why?
|
| Plasmids | 1 | 2010 | 2307 | 0.060 |
Why?
|
| Human T-lymphotropic virus 2 | 2 | 1996 | 10 | 0.060 |
Why?
|
| Antigen Presentation | 1 | 2010 | 1284 | 0.060 |
Why?
|
| Kinetics | 3 | 2011 | 6474 | 0.060 |
Why?
|
| Deltaretrovirus Antigens | 2 | 1995 | 3 | 0.060 |
Why?
|
| Cytopathogenic Effect, Viral | 2 | 1994 | 156 | 0.060 |
Why?
|
| C-Reactive Protein | 2 | 2020 | 3778 | 0.060 |
Why?
|
| Cytotoxicity, Immunologic | 3 | 2002 | 1368 | 0.060 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2005 | 257 | 0.060 |
Why?
|
| Prevalence | 4 | 2020 | 15226 | 0.060 |
Why?
|
| Drug Resistance | 4 | 2000 | 1608 | 0.060 |
Why?
|
| Vaccines, Synthetic | 2 | 2012 | 634 | 0.060 |
Why?
|
| Treatment Refusal | 1 | 2007 | 421 | 0.060 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2014 | 1352 | 0.060 |
Why?
|
| Selection, Genetic | 1 | 2009 | 914 | 0.060 |
Why?
|
| Genes, MDR | 1 | 2003 | 37 | 0.060 |
Why?
|
| Operon | 2 | 1985 | 363 | 0.060 |
Why?
|
| Virulence | 1 | 2008 | 1333 | 0.060 |
Why?
|
| Models, Theoretical | 1 | 2016 | 3591 | 0.060 |
Why?
|
| Counseling | 1 | 2012 | 1523 | 0.060 |
Why?
|
| Regression Analysis | 4 | 2007 | 6461 | 0.060 |
Why?
|
| Nucleosides | 1 | 2004 | 138 | 0.060 |
Why?
|
| Mutagenesis | 2 | 2004 | 1267 | 0.060 |
Why?
|
| Aging | 2 | 2015 | 8661 | 0.060 |
Why?
|
| Prisoners | 1 | 2006 | 297 | 0.060 |
Why?
|
| Equipment Failure Analysis | 3 | 2012 | 868 | 0.060 |
Why?
|
| Equipment Design | 4 | 2015 | 3582 | 0.060 |
Why?
|
| Telemedicine | 1 | 2020 | 2872 | 0.060 |
Why?
|
| Intestinal Mucosa | 1 | 2014 | 3036 | 0.060 |
Why?
|
| Uganda | 1 | 2008 | 1243 | 0.060 |
Why?
|
| Biological Evolution | 1 | 2009 | 1076 | 0.060 |
Why?
|
| Linear Models | 2 | 2010 | 5953 | 0.060 |
Why?
|
| Child, Preschool | 8 | 2022 | 40992 | 0.050 |
Why?
|
| RNA | 2 | 2023 | 2749 | 0.050 |
Why?
|
| Poverty Areas | 1 | 2004 | 275 | 0.050 |
Why?
|
| HeLa Cells | 2 | 2007 | 3129 | 0.050 |
Why?
|
| Pattern Recognition, Automated | 1 | 2009 | 1005 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3132 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3239 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 4 | 2020 | 7281 | 0.050 |
Why?
|
| Cloning, Molecular | 2 | 2006 | 4321 | 0.050 |
Why?
|
| Clone Cells | 2 | 2002 | 1692 | 0.050 |
Why?
|
| Cytotoxicity Tests, Immunologic | 2 | 2001 | 329 | 0.050 |
Why?
|
| Social Justice | 1 | 2006 | 456 | 0.050 |
Why?
|
| Complementarity Determining Regions | 1 | 2002 | 149 | 0.050 |
Why?
|
| Molecular Epidemiology | 1 | 2004 | 468 | 0.050 |
Why?
|
| Genetic Markers | 2 | 2001 | 2634 | 0.050 |
Why?
|
| Genes, Viral | 3 | 1999 | 718 | 0.050 |
Why?
|
| Antigens, CD | 3 | 2015 | 4026 | 0.050 |
Why?
|
| Genes, nef | 1 | 2001 | 55 | 0.050 |
Why?
|
| Furans | 2 | 2001 | 194 | 0.050 |
Why?
|
| Mothers | 2 | 2024 | 2165 | 0.050 |
Why?
|
| Sex Factors | 2 | 2012 | 10396 | 0.050 |
Why?
|
| Blood-Brain Barrier | 1 | 2008 | 1016 | 0.050 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2006 | 602 | 0.050 |
Why?
|
| Nanoparticles | 1 | 2013 | 1905 | 0.050 |
Why?
|
| Immunotherapy | 3 | 2012 | 4440 | 0.050 |
Why?
|
| Carbamates | 2 | 2001 | 196 | 0.050 |
Why?
|
| Bayes Theorem | 4 | 2016 | 2309 | 0.050 |
Why?
|
| Reference Standards | 2 | 2015 | 1025 | 0.050 |
Why?
|
| Energy Metabolism | 2 | 2003 | 2895 | 0.050 |
Why?
|
| Immune System | 2 | 2012 | 805 | 0.050 |
Why?
|
| Interferon-gamma | 3 | 2010 | 3203 | 0.050 |
Why?
|
| Genomic Instability | 1 | 2005 | 695 | 0.050 |
Why?
|
| Lipodystrophy | 1 | 2001 | 147 | 0.050 |
Why?
|
| Alcohol Oxidoreductases | 1 | 2001 | 170 | 0.050 |
Why?
|
| Adenosine Monophosphate | 1 | 2022 | 275 | 0.050 |
Why?
|
| Sulfuric Acid Esters | 1 | 2020 | 33 | 0.050 |
Why?
|
| Genes | 2 | 1984 | 1893 | 0.050 |
Why?
|
| Adipose Tissue | 2 | 2003 | 3278 | 0.050 |
Why?
|
| Time-Lapse Imaging | 1 | 2021 | 195 | 0.050 |
Why?
|
| Integrases | 1 | 2023 | 533 | 0.050 |
Why?
|
| Antitubercular Agents | 1 | 2008 | 1320 | 0.050 |
Why?
|
| Histocytochemistry | 1 | 2021 | 719 | 0.050 |
Why?
|
| Inflammation | 4 | 2023 | 10634 | 0.050 |
Why?
|
| Alanine | 1 | 2022 | 572 | 0.050 |
Why?
|
| Complement Pathway, Classical | 1 | 1999 | 97 | 0.040 |
Why?
|
| Genes, Bacterial | 1 | 1984 | 1079 | 0.040 |
Why?
|
| Immunity, Cellular | 2 | 2008 | 1607 | 0.040 |
Why?
|
| Leukapheresis | 1 | 2000 | 131 | 0.040 |
Why?
|
| Viral Hepatitis Vaccines | 1 | 2000 | 80 | 0.040 |
Why?
|
| Gene Products, pol | 1 | 1999 | 47 | 0.040 |
Why?
|
| Hypersensitivity, Delayed | 4 | 2003 | 485 | 0.040 |
Why?
|
| Communicable Disease Control | 2 | 2020 | 857 | 0.040 |
Why?
|
| Succinate Dehydrogenase | 3 | 1986 | 146 | 0.040 |
Why?
|
| AIDS Serodiagnosis | 1 | 2020 | 184 | 0.040 |
Why?
|
| Confidentiality | 1 | 2003 | 612 | 0.040 |
Why?
|
| Lenses | 2 | 2009 | 45 | 0.040 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 12244 | 0.040 |
Why?
|
| T-Lymphocyte Subsets | 4 | 2002 | 1838 | 0.040 |
Why?
|
| Salmonella typhimurium | 1 | 2001 | 351 | 0.040 |
Why?
|
| Mycobacterium avium-intracellulare Infection | 1 | 1999 | 76 | 0.040 |
Why?
|
| Adenosine Triphosphate | 1 | 2005 | 2025 | 0.040 |
Why?
|
| Logistic Models | 5 | 2013 | 13409 | 0.040 |
Why?
|
| Fluorescence | 2 | 2013 | 751 | 0.040 |
Why?
|
| Defective Viruses | 1 | 2018 | 112 | 0.040 |
Why?
|
| Thermodynamics | 1 | 2020 | 596 | 0.040 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2002 | 805 | 0.040 |
Why?
|
| Neuropsychology | 1 | 2019 | 110 | 0.040 |
Why?
|
| Species Specificity | 4 | 2014 | 2480 | 0.040 |
Why?
|
| Demography | 1 | 2023 | 1656 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 2 | 2020 | 2013 | 0.040 |
Why?
|
| Estrogen Receptor alpha | 1 | 2022 | 577 | 0.040 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2019 | 264 | 0.040 |
Why?
|
| Specimen Handling | 1 | 2003 | 694 | 0.040 |
Why?
|
| Hospitals | 2 | 2022 | 3952 | 0.040 |
Why?
|
| Consensus Sequence | 1 | 1998 | 377 | 0.040 |
Why?
|
| Biological Specimen Banks | 1 | 2003 | 712 | 0.040 |
Why?
|
| Thymus Gland | 2 | 2000 | 1267 | 0.040 |
Why?
|
| Immunologic Memory | 2 | 2001 | 1348 | 0.040 |
Why?
|
| Dietary Carbohydrates | 1 | 2003 | 906 | 0.040 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 1998 | 517 | 0.040 |
Why?
|
| Risk Factors | 7 | 2020 | 72280 | 0.040 |
Why?
|
| Alkaline Phosphatase | 1 | 2001 | 865 | 0.040 |
Why?
|
| Health Resources | 1 | 2004 | 911 | 0.040 |
Why?
|
| Saquinavir | 1 | 1997 | 28 | 0.040 |
Why?
|
| Chromosomes, Human | 1 | 2019 | 457 | 0.040 |
Why?
|
| Intention | 1 | 2020 | 341 | 0.040 |
Why?
|
| Algorithms | 5 | 2020 | 13885 | 0.040 |
Why?
|
| Body Composition | 5 | 2007 | 2400 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 2003 | 1462 | 0.040 |
Why?
|
| Oxygen Consumption | 1 | 1984 | 1869 | 0.040 |
Why?
|
| Cell Adhesion Molecules | 1 | 2023 | 1602 | 0.040 |
Why?
|
| Follow-Up Studies | 6 | 2020 | 39045 | 0.040 |
Why?
|
| Antibodies, Viral | 2 | 2020 | 3176 | 0.040 |
Why?
|
| Disease Outbreaks | 1 | 2006 | 1772 | 0.040 |
Why?
|
| Sulfonic Acids | 1 | 1997 | 96 | 0.040 |
Why?
|
| Paper | 1 | 2017 | 85 | 0.040 |
Why?
|
| DNA | 2 | 2022 | 7303 | 0.040 |
Why?
|
| Phytohemagglutinins | 1 | 1996 | 170 | 0.040 |
Why?
|
| Glutathione | 1 | 2019 | 588 | 0.040 |
Why?
|
| Position-Specific Scoring Matrices | 1 | 2016 | 11 | 0.040 |
Why?
|
| Aged | 14 | 2020 | 163253 | 0.040 |
Why?
|
| Risk Assessment | 4 | 2020 | 23337 | 0.040 |
Why?
|
| History, 20th Century | 1 | 2004 | 2739 | 0.040 |
Why?
|
| Graphite | 1 | 2017 | 66 | 0.040 |
Why?
|
| Streptokinase | 1 | 1996 | 188 | 0.040 |
Why?
|
| DNA Ligases | 1 | 1996 | 80 | 0.040 |
Why?
|
| Complement System Proteins | 1 | 1999 | 795 | 0.040 |
Why?
|
| Membrane Glycoproteins | 3 | 2011 | 3769 | 0.030 |
Why?
|
| Biological Transport, Active | 1 | 2016 | 349 | 0.030 |
Why?
|
| Trifluridine | 1 | 1996 | 29 | 0.030 |
Why?
|
| Zalcitabine | 1 | 1995 | 42 | 0.030 |
Why?
|
| Silver | 1 | 2017 | 122 | 0.030 |
Why?
|
| Glutamine | 1 | 2019 | 578 | 0.030 |
Why?
|
| Databases, Genetic | 1 | 2003 | 1782 | 0.030 |
Why?
|
| Solubility | 1 | 2018 | 1083 | 0.030 |
Why?
|
| Retroviridae Proteins, Oncogenic | 1 | 1995 | 76 | 0.030 |
Why?
|
| Public Health | 2 | 2020 | 2603 | 0.030 |
Why?
|
| Microscopy | 1 | 2021 | 903 | 0.030 |
Why?
|
| Adipocytes | 1 | 2003 | 1182 | 0.030 |
Why?
|
| Benzoxazoles | 1 | 1996 | 77 | 0.030 |
Why?
|
| Neonatal Screening | 1 | 2020 | 591 | 0.030 |
Why?
|
| Giant Cells | 1 | 1996 | 187 | 0.030 |
Why?
|
| Age Factors | 1 | 2012 | 18367 | 0.030 |
Why?
|
| Protein Conformation | 2 | 2016 | 4012 | 0.030 |
Why?
|
| Isoquinolines | 1 | 1997 | 368 | 0.030 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2003 | 1676 | 0.030 |
Why?
|
| Antigens, Neoplasm | 1 | 2023 | 1987 | 0.030 |
Why?
|
| Prognosis | 6 | 2010 | 29050 | 0.030 |
Why?
|
| Glucose Tolerance Test | 3 | 2003 | 1150 | 0.030 |
Why?
|
| Embryo, Mammalian | 1 | 2021 | 1701 | 0.030 |
Why?
|
| Plasmacytoma | 1 | 1995 | 183 | 0.030 |
Why?
|
| Platelet Count | 1 | 1998 | 781 | 0.030 |
Why?
|
| Retrospective Studies | 10 | 2014 | 77426 | 0.030 |
Why?
|
| Recurrence | 2 | 2017 | 8343 | 0.030 |
Why?
|
| Health Services Accessibility | 3 | 2013 | 5138 | 0.030 |
Why?
|
| DNA Mutational Analysis | 2 | 2000 | 4188 | 0.030 |
Why?
|
| Leptin | 1 | 2003 | 1599 | 0.030 |
Why?
|
| Receptors, CCR2 | 1 | 2015 | 212 | 0.030 |
Why?
|
| Mycoses | 1 | 1998 | 376 | 0.030 |
Why?
|
| Limit of Detection | 1 | 2015 | 265 | 0.030 |
Why?
|
| Condoms | 1 | 2016 | 323 | 0.030 |
Why?
|
| Therapeutic Equivalency | 1 | 2014 | 145 | 0.030 |
Why?
|
| Disaster Planning | 1 | 2020 | 548 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2023 | 2540 | 0.030 |
Why?
|
| Osmolar Concentration | 1 | 2015 | 683 | 0.030 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2020 | 783 | 0.030 |
Why?
|
| Organizational Objectives | 1 | 2016 | 438 | 0.030 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 1998 | 880 | 0.030 |
Why?
|
| Neutralization Tests | 1 | 2016 | 758 | 0.030 |
Why?
|
| Cell Division | 2 | 1999 | 4567 | 0.030 |
Why?
|
| Cell Fusion | 1 | 1994 | 297 | 0.030 |
Why?
|
| Drug Design | 1 | 1999 | 1078 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2015 | 17449 | 0.030 |
Why?
|
| In Situ Hybridization | 1 | 2018 | 1950 | 0.030 |
Why?
|
| Combined Modality Therapy | 2 | 2018 | 8628 | 0.030 |
Why?
|
| HLA-DR Antigens | 1 | 2015 | 645 | 0.030 |
Why?
|
| Blood Preservation | 1 | 1994 | 177 | 0.030 |
Why?
|
| Glutamic Acid | 1 | 2019 | 1169 | 0.030 |
Why?
|
| Social Stigma | 1 | 2020 | 701 | 0.030 |
Why?
|
| Herpesviridae Infections | 1 | 2015 | 277 | 0.030 |
Why?
|
| Massachusetts | 2 | 2020 | 8663 | 0.030 |
Why?
|
| Proteome | 1 | 2023 | 1798 | 0.030 |
Why?
|
| Models, Economic | 1 | 2017 | 713 | 0.030 |
Why?
|
| Transfection | 1 | 2001 | 5892 | 0.030 |
Why?
|
| Models, Molecular | 2 | 2016 | 5458 | 0.030 |
Why?
|
| Tuberculosis, Cutaneous | 1 | 1993 | 17 | 0.030 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2019 | 1123 | 0.030 |
Why?
|
| Suppuration | 1 | 1992 | 56 | 0.030 |
Why?
|
| Telomere | 1 | 1999 | 910 | 0.030 |
Why?
|
| Dielectric Spectroscopy | 1 | 2013 | 32 | 0.030 |
Why?
|
| Polystyrenes | 1 | 2013 | 112 | 0.030 |
Why?
|
| Health Personnel | 1 | 2006 | 3216 | 0.030 |
Why?
|
| Quality of Life | 2 | 2020 | 12805 | 0.030 |
Why?
|
| Hospitalization | 3 | 2020 | 10262 | 0.030 |
Why?
|
| Cross-Sectional Studies | 7 | 2012 | 25043 | 0.030 |
Why?
|
| Herpes Simplex | 1 | 1996 | 470 | 0.030 |
Why?
|
| Cell Death | 1 | 2018 | 1708 | 0.030 |
Why?
|
| Catalase | 1 | 1992 | 222 | 0.030 |
Why?
|
| Sexual Partners | 1 | 2016 | 730 | 0.030 |
Why?
|
| Anaerobiosis | 4 | 1986 | 140 | 0.030 |
Why?
|
| Caregivers | 1 | 2024 | 2094 | 0.030 |
Why?
|
| Histones | 1 | 2022 | 2600 | 0.030 |
Why?
|
| HLA Antigens | 2 | 2011 | 1382 | 0.030 |
Why?
|
| Antibiotics, Antitubercular | 1 | 2012 | 104 | 0.030 |
Why?
|
| Safety | 3 | 2005 | 1185 | 0.030 |
Why?
|
| ROC Curve | 2 | 2013 | 3527 | 0.030 |
Why?
|
| Placenta | 1 | 2001 | 1697 | 0.030 |
Why?
|
| Vaginal Creams, Foams, and Jellies | 1 | 2011 | 63 | 0.030 |
Why?
|
| Human T-lymphotropic virus 1 | 1 | 1992 | 140 | 0.030 |
Why?
|
| Administration, Intravaginal | 1 | 2011 | 150 | 0.030 |
Why?
|
| Plasmodium falciparum | 1 | 2021 | 1732 | 0.020 |
Why?
|
| Respiration, Artificial | 1 | 2022 | 2569 | 0.020 |
Why?
|
| Qualitative Research | 1 | 2020 | 2682 | 0.020 |
Why?
|
| Pyridines | 3 | 2014 | 2822 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2017 | 1531 | 0.020 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 1992 | 305 | 0.020 |
Why?
|
| Pandemics | 2 | 2021 | 8387 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2020 | 3201 | 0.020 |
Why?
|
| Oxygen | 1 | 2022 | 4187 | 0.020 |
Why?
|
| Antigens, Bacterial | 1 | 1996 | 1171 | 0.020 |
Why?
|
| HLA-C Antigens | 1 | 2010 | 147 | 0.020 |
Why?
|
| Immunoconjugates | 1 | 2018 | 901 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2015 | 2557 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2016 | 3133 | 0.020 |
Why?
|
| Lipids | 2 | 2015 | 3305 | 0.020 |
Why?
|
| Volatilization | 1 | 1990 | 82 | 0.020 |
Why?
|
| HLA-A Antigens | 1 | 2010 | 231 | 0.020 |
Why?
|
| Rural Population | 1 | 2020 | 2210 | 0.020 |
Why?
|
| Steam | 1 | 1990 | 31 | 0.020 |
Why?
|
| Sequence Deletion | 1 | 2014 | 1526 | 0.020 |
Why?
|
| Developmental Disabilities | 1 | 2018 | 1456 | 0.020 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2001 | 2752 | 0.020 |
Why?
|
| Outpatients | 1 | 1998 | 1486 | 0.020 |
Why?
|
| Dendritic Cells | 1 | 2001 | 2725 | 0.020 |
Why?
|
| Health Policy | 2 | 2017 | 2661 | 0.020 |
Why?
|
| Cell Separation | 1 | 2015 | 1751 | 0.020 |
Why?
|
| International Cooperation | 1 | 2016 | 1421 | 0.020 |
Why?
|
| Cryopreservation | 1 | 1994 | 670 | 0.020 |
Why?
|
| Mutant Proteins | 1 | 2011 | 500 | 0.020 |
Why?
|
| Monitoring, Physiologic | 1 | 1997 | 1737 | 0.020 |
Why?
|
| Longitudinal Studies | 2 | 2020 | 13990 | 0.020 |
Why?
|
| Polymorphism, Genetic | 3 | 2007 | 4328 | 0.020 |
Why?
|
| Mycobacterium avium Complex | 1 | 2009 | 60 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2016 | 3588 | 0.020 |
Why?
|
| Oligopeptides | 1 | 2014 | 1178 | 0.020 |
Why?
|
| Environment | 1 | 2015 | 1124 | 0.020 |
Why?
|
| Gene Amplification | 3 | 2003 | 1062 | 0.020 |
Why?
|
| Surface Properties | 1 | 2012 | 1184 | 0.020 |
Why?
|
| Homosexuality, Male | 1 | 2016 | 1240 | 0.020 |
Why?
|
| Temperature | 1 | 2015 | 2206 | 0.020 |
Why?
|
| Tropism | 1 | 2008 | 41 | 0.020 |
Why?
|
| Predictive Value of Tests | 4 | 2011 | 15070 | 0.020 |
Why?
|
| Arginine | 1 | 2012 | 944 | 0.020 |
Why?
|
| Radioisotopes | 1 | 1990 | 499 | 0.020 |
Why?
|
| Occupational Exposure | 1 | 1999 | 1796 | 0.020 |
Why?
|
| Human Immunodeficiency Virus Proteins | 1 | 2008 | 65 | 0.020 |
Why?
|
| Software | 2 | 2018 | 4442 | 0.020 |
Why?
|
| Transplantation Immunology | 1 | 2010 | 547 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2019 | 3085 | 0.020 |
Why?
|
| Computational Biology | 1 | 2000 | 3523 | 0.020 |
Why?
|
| Blood Transfusion | 1 | 1994 | 1296 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2003 | 4599 | 0.020 |
Why?
|
| Lysine | 1 | 2012 | 1008 | 0.020 |
Why?
|
| Gram-Positive Bacteria | 1 | 1988 | 184 | 0.020 |
Why?
|
| Proteins | 1 | 2003 | 6101 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2014 | 3846 | 0.020 |
Why?
|
| Attitude to Health | 1 | 2016 | 2053 | 0.020 |
Why?
|
| Nonlinear Dynamics | 1 | 2010 | 502 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2016 | 15525 | 0.020 |
Why?
|
| Ambulatory Care Facilities | 1 | 2013 | 933 | 0.020 |
Why?
|
| Libya | 1 | 2006 | 9 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 2 | 1998 | 7179 | 0.020 |
Why?
|
| Systems Integration | 1 | 2009 | 440 | 0.020 |
Why?
|
| Blood Glucose | 2 | 2015 | 6259 | 0.020 |
Why?
|
| Nanomedicine | 1 | 2010 | 304 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2000 | 10250 | 0.020 |
Why?
|
| Tanzania | 1 | 2011 | 1346 | 0.020 |
Why?
|
| Lactates | 1 | 2007 | 432 | 0.020 |
Why?
|
| Jurisprudence | 1 | 2006 | 110 | 0.020 |
Why?
|
| Radiation Protection | 1 | 1990 | 419 | 0.020 |
Why?
|
| Drug Carriers | 1 | 2011 | 693 | 0.020 |
Why?
|
| Boston | 1 | 2019 | 9311 | 0.020 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 1993 | 810 | 0.020 |
Why?
|
| Insulin Resistance | 3 | 2007 | 3863 | 0.020 |
Why?
|
| Anemia, Sickle Cell | 1 | 2014 | 1018 | 0.020 |
Why?
|
| Immunization | 1 | 2010 | 1256 | 0.020 |
Why?
|
| Pregnancy Complications | 1 | 2020 | 2862 | 0.020 |
Why?
|
| Graft vs Host Disease | 1 | 2018 | 2957 | 0.020 |
Why?
|
| Health Services Administration | 1 | 2006 | 64 | 0.020 |
Why?
|
| Vancomycin | 1 | 1988 | 501 | 0.020 |
Why?
|
| Macaca mulatta | 1 | 2011 | 2378 | 0.020 |
Why?
|
| Infant, Premature | 1 | 1994 | 2044 | 0.020 |
Why?
|
| Pyrones | 1 | 2004 | 36 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2017 | 3528 | 0.020 |
Why?
|
| Cilia | 1 | 1988 | 466 | 0.020 |
Why?
|
| Odds Ratio | 2 | 2011 | 9849 | 0.020 |
Why?
|
| Incidence | 1 | 2003 | 20945 | 0.020 |
Why?
|
| Gene Transfer Techniques | 1 | 2010 | 1224 | 0.020 |
Why?
|
| Kidney Diseases | 2 | 2008 | 2147 | 0.020 |
Why?
|
| Amino Acids | 1 | 2010 | 1734 | 0.020 |
Why?
|
| Viral Proteins | 1 | 2011 | 1900 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2016 | 3741 | 0.020 |
Why?
|
| Haplotypes | 1 | 2010 | 2781 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2018 | 7723 | 0.010 |
Why?
|
| CD4-CD8 Ratio | 1 | 2003 | 112 | 0.010 |
Why?
|
| Mathematics | 1 | 2005 | 728 | 0.010 |
Why?
|
| Chromatography, Liquid | 1 | 2008 | 977 | 0.010 |
Why?
|
| Lymphatic Diseases | 1 | 2005 | 324 | 0.010 |
Why?
|
| Hot Temperature | 1 | 1990 | 1355 | 0.010 |
Why?
|
| Disease Management | 1 | 2014 | 2458 | 0.010 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2005 | 282 | 0.010 |
Why?
|
| Protein Binding | 1 | 2016 | 9392 | 0.010 |
Why?
|
| Cell Proliferation | 2 | 2010 | 10480 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2020 | 8950 | 0.010 |
Why?
|
| Cross Infection | 1 | 1993 | 1416 | 0.010 |
Why?
|
| Animals | 8 | 2011 | 168788 | 0.010 |
Why?
|
| Cross-Over Studies | 2 | 2001 | 2032 | 0.010 |
Why?
|
| Drug Tolerance | 1 | 2005 | 376 | 0.010 |
Why?
|
| Pulse Therapy, Drug | 1 | 2002 | 35 | 0.010 |
Why?
|
| Mice, SCID | 2 | 2000 | 2716 | 0.010 |
Why?
|
| Population Surveillance | 1 | 2013 | 2616 | 0.010 |
Why?
|
| Calorimetry, Indirect | 1 | 2003 | 183 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 15538 | 0.010 |
Why?
|
| Nausea | 1 | 2005 | 668 | 0.010 |
Why?
|
| Health Planning Guidelines | 1 | 2003 | 163 | 0.010 |
Why?
|
| Genes, T-Cell Receptor beta | 1 | 2002 | 71 | 0.010 |
Why?
|
| Organizations | 1 | 2003 | 170 | 0.010 |
Why?
|
| Lymphocyte Subsets | 1 | 2003 | 315 | 0.010 |
Why?
|
| Age Distribution | 1 | 2008 | 2903 | 0.010 |
Why?
|
| Sample Size | 1 | 2006 | 846 | 0.010 |
Why?
|
| Immunity | 1 | 2008 | 1012 | 0.010 |
Why?
|
| Lactic Acid | 1 | 2007 | 1132 | 0.010 |
Why?
|
| Metabolic Diseases | 1 | 2008 | 658 | 0.010 |
Why?
|
| Retinal Diseases | 1 | 1987 | 683 | 0.010 |
Why?
|
| Injections, Subcutaneous | 1 | 2003 | 665 | 0.010 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2008 | 1157 | 0.010 |
Why?
|
| Multienzyme Complexes | 1 | 1985 | 686 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2011 | 3420 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2011 | 3494 | 0.010 |
Why?
|
| Probability | 1 | 2007 | 2505 | 0.010 |
Why?
|
| Diagnostic Errors | 1 | 1988 | 1255 | 0.010 |
Why?
|
| RNA, Small Interfering | 1 | 2010 | 3505 | 0.010 |
Why?
|
| Organ Transplantation | 1 | 2010 | 1139 | 0.010 |
Why?
|
| Mumps virus | 1 | 2000 | 24 | 0.010 |
Why?
|
| Hepatitis A Vaccines | 1 | 2000 | 29 | 0.010 |
Why?
|
| Apoptosis | 3 | 2003 | 9728 | 0.010 |
Why?
|
| Injections, Intradermal | 1 | 2000 | 117 | 0.010 |
Why?
|
| Neurons | 1 | 2019 | 9335 | 0.010 |
Why?
|
| Liver Diseases | 1 | 2008 | 1254 | 0.010 |
Why?
|
| Lac Operon | 1 | 1979 | 238 | 0.010 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2004 | 525 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2013 | 7784 | 0.010 |
Why?
|
| ADP-ribosyl Cyclase | 1 | 1999 | 38 | 0.010 |
Why?
|
| Acute Disease | 1 | 2010 | 7148 | 0.010 |
Why?
|
| North America | 1 | 2003 | 1250 | 0.010 |
Why?
|
| NAD+ Nucleosidase | 1 | 1999 | 39 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2015 | 16687 | 0.010 |
Why?
|
| Restriction Mapping | 1 | 1999 | 878 | 0.010 |
Why?
|
| Brazil | 1 | 2003 | 1270 | 0.010 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2000 | 1375 | 0.010 |
Why?
|
| Sequence Analysis, Protein | 1 | 2000 | 258 | 0.010 |
Why?
|
| Diarrhea | 1 | 2005 | 1347 | 0.010 |
Why?
|
| Sequence Analysis | 1 | 1999 | 256 | 0.010 |
Why?
|
| Anthropometry | 1 | 2003 | 1350 | 0.010 |
Why?
|
| Multicenter Studies as Topic | 1 | 2003 | 1677 | 0.010 |
Why?
|
| Fatigue | 1 | 2005 | 1531 | 0.010 |
Why?
|
| Hemoglobins | 1 | 2004 | 1533 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2007 | 6367 | 0.010 |
Why?
|
| Fas Ligand Protein | 1 | 1998 | 217 | 0.010 |
Why?
|
| Tomography | 1 | 2000 | 390 | 0.010 |
Why?
|
| Oxidation-Reduction | 1 | 2003 | 2187 | 0.010 |
Why?
|
| Absorptiometry, Photon | 1 | 2003 | 1725 | 0.010 |
Why?
|
| Abdomen | 1 | 2003 | 1118 | 0.010 |
Why?
|
| Adiponectin | 1 | 2003 | 1100 | 0.010 |
Why?
|
| Antipyrine | 1 | 1996 | 40 | 0.010 |
Why?
|
| Retroviridae | 1 | 1999 | 914 | 0.010 |
Why?
|
| Hemagglutinins, Viral | 1 | 1995 | 67 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 1988 | 3690 | 0.010 |
Why?
|
| Bacterial Proteins | 2 | 1986 | 3849 | 0.010 |
Why?
|
| Antigens, Differentiation | 1 | 1999 | 927 | 0.010 |
Why?
|
| Acyclovir | 1 | 1996 | 272 | 0.010 |
Why?
|
| Body Mass Index | 2 | 2003 | 12718 | 0.010 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2010 | 3712 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2018 | 13668 | 0.010 |
Why?
|
| Blood Specimen Collection | 1 | 1996 | 246 | 0.010 |
Why?
|
| Chronic Disease | 2 | 2002 | 9147 | 0.010 |
Why?
|
| Hemagglutinin Glycoproteins, Influenza Virus | 1 | 1995 | 157 | 0.010 |
Why?
|
| Nitrates | 2 | 1986 | 265 | 0.010 |
Why?
|
| Administration, Topical | 1 | 1996 | 689 | 0.010 |
Why?
|
| Vaccinia virus | 1 | 1996 | 349 | 0.010 |
Why?
|
| Cell Transformation, Viral | 1 | 1995 | 565 | 0.010 |
Why?
|
| Liver | 1 | 2010 | 7472 | 0.010 |
Why?
|
| Aerobiosis | 2 | 1986 | 106 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1996 | 1676 | 0.010 |
Why?
|
| Pneumonia | 1 | 2005 | 2134 | 0.010 |
Why?
|
| HTLV-II Antigens | 1 | 1992 | 1 | 0.010 |
Why?
|
| HTLV-II Antibodies | 1 | 1992 | 3 | 0.010 |
Why?
|
| HTLV-I Antigens | 1 | 1992 | 7 | 0.010 |
Why?
|
| Deltaretrovirus Antibodies | 1 | 1992 | 9 | 0.010 |
Why?
|
| Radioimmunoprecipitation Assay | 1 | 1992 | 16 | 0.010 |
Why?
|
| HTLV-I Antibodies | 1 | 1992 | 35 | 0.010 |
Why?
|
| Antigens | 1 | 1998 | 1466 | 0.010 |
Why?
|
| Body Weight | 1 | 2003 | 4666 | 0.010 |
Why?
|
| Immune Sera | 1 | 1992 | 641 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2010 | 12264 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2006 | 13036 | 0.010 |
Why?
|
| Cell Cycle | 1 | 1999 | 2967 | 0.010 |
Why?
|
| Waste Disposal, Fluid | 1 | 1990 | 30 | 0.010 |
Why?
|
| Cross Reactions | 1 | 1992 | 841 | 0.010 |
Why?
|
| Spleen | 1 | 1995 | 2361 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2003 | 5102 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2001 | 9735 | 0.010 |
Why?
|
| Mice | 3 | 2001 | 81178 | 0.000 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1992 | 2505 | 0.000 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2002 | 3923 | 0.000 |
Why?
|
| Sleep | 1 | 2003 | 4623 | 0.000 |
Why?
|
| Immunoglobulin G | 1 | 1999 | 4559 | 0.000 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1995 | 3772 | 0.000 |
Why?
|
| Succinates | 1 | 1986 | 83 | 0.000 |
Why?
|
| Mice, Inbred BALB C | 1 | 1995 | 6386 | 0.000 |
Why?
|
| Suppression, Genetic | 1 | 1986 | 196 | 0.000 |
Why?
|
| Succinic Acid | 1 | 1986 | 83 | 0.000 |
Why?
|
| Enzyme Induction | 1 | 1986 | 475 | 0.000 |
Why?
|
| Rabbits | 1 | 1992 | 4892 | 0.000 |
Why?
|
| Epitopes | 1 | 1992 | 2571 | 0.000 |
Why?
|
| B-Lymphocytes | 1 | 1998 | 4665 | 0.000 |
Why?
|
| Diet | 1 | 2003 | 7937 | 0.000 |
Why?
|
| Genes, Regulator | 1 | 1985 | 378 | 0.000 |
Why?
|
| Aged, 80 and over | 1 | 2005 | 57768 | 0.000 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2003 | 20123 | 0.000 |
Why?
|
| beta-Galactosidase | 1 | 1979 | 573 | 0.000 |
Why?
|
| Gene Expression Regulation | 2 | 1986 | 12075 | 0.000 |
Why?
|
| Retina | 1 | 1987 | 2616 | 0.000 |
Why?
|
| Environmental Exposure | 1 | 1990 | 4236 | 0.000 |
Why?
|
| Immunohistochemistry | 1 | 1987 | 11368 | 0.000 |
Why?
|